Welcome to our dedicated page for Innovent Biologics news (Ticker: $IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innovent Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innovent Biologics's position in the market.
News
Rhea-AI Summary
Innovent Biologics, Inc. announces the presentation of preclinical data on multiple novel bispecific antibodies and antibody-drug-conjugates from its oncology pipeline at the AACR Annual Meeting 2024. The company aims to develop next-generation therapies to tackle drug resistance and enhance treatment outcomes in immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. announced positive results from two clinical studies of IBI311, showing safety and efficacy in healthy subjects and patients with thyroid eye disease. The studies demonstrated that IBI311 significantly improved proptosis in patients with TED, with a favorable safety profile. The results were presented at prestigious medical congresses, highlighting the potential of IBI311 as a targeted therapy for thyroid ophthalmopathy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics and AnHeart Therapeutics announce the acceptance of a second New Drug Application for taletrectinib as a first-line treatment for ROS1-positive non-small cell lung cancer in China. The NDA is based on positive Phase 2 trial results, with additional data expected in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics, Inc. announces the initiation of a phase 1 clinical trial for IBI3002, a bispecific antibody targeting IL-4Rα and TSLP, showing potential in treating inflammatory diseases like asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20.83%
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. achieves primary endpoint in Phase 3 study of IBI311 for Thyroid Eye Disease, showing significant efficacy and safety. Plans to submit NDA for IBI311 to NMPA. Detailed results to be shared in future conferences or journals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. announces the acceptance of the New Drug Application (NDA) for mazdutide, a GLP-1R/GCGR dual agonist, by the National Medical Products Administration (NMPA) of China for chronic weight management in adults with obesity or overweight. The Phase 3 clinical trial of mazdutide in Chinese adults with overweight or obesity met primary and secondary endpoints, showing superiority over placebo in terms of body weight reduction and cardiometabolic endpoints. The safety profile was similar to previous clinical studies, with no new safety signals observed. The leading principal investigator of the study, Professor Linong Ji, emphasized the potential benefits of mazdutide in reducing chronic disease risks, and Dr. Lei Qian, Vice President of Clinical Development of Innovent, highlighted the potential of mazdutide as a next-generation GLP-1-based anti-obesity drug with robust weight-loss efficacy and cardiometabolic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics, Inc. (IVBIY) announced the retirement of CFO Mr. Ronald Hao Xi Ede after a seven-year tenure, with Ms. Fei You appointed as the new CFO. Mr. Ede will continue as an executive director and managing partner of the Company's funds. Ms. You brings over 20 years of experience in financial management and strategic investment. Innovent's Founder, Chairman, and CEO, Dr. Michael Yu, expressed gratitude towards Mr. Ede's contributions and welcomed Ms. You as the new CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces successful Phase 3 trial of mazdutide for weight management in Chinese adults with overweight or obesity, meeting primary and key secondary endpoints with positive safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces the successful dosing of the first participant in a Phase 3 clinical trial of mazdutide, a dual agonist for Chinese adults with obesity, showing promising results from a Phase 2 study. The drug demonstrated an 18.6% placebo-adjusted mean percent reduction in body weight and multiple metabolic benefits in Chinese people with obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) and Xuanzhu Biopharma announce a clinical trial collaboration and supply agreement for the combination therapies of TYVYT® (sintilimab injection) with KM-501 for advanced solid tumors in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Innovent Biologics Inc
OTC:IVBIY
IVBIY Rankings
IVBIY Stock Data
7.84B
1.38B
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
United States of America
Suzhou